Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of siG12D-LODER plus standard chemotherapy in locally advanced unresectable pancreatic cancer
MOH_2018-06-26_002480Phase 2Recruiting
- Sponsor
- Silenseed
- Start
- Jun 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siG12D-LODER in pancreatic adenocarcinoma (PDAC), sponsored by Silenseed. Started Jun 2018; status: recruiting.
02
Drugs
siG12D-LODER
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2018-06-26_002480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-26_002480.